Human single-administration dose-ranging
- Reported quantity
- 30, 60 and 125 µg/kg arms
- Frequency
- Single administration
- Study duration
- Sampling across 14 days
IGF-1 remained elevated for 6–11 days after one administration in these arms.
Protocols · Growth Hormone
CJC-1295 with DAC: literature-reported ranges
The DAC version binds serum albumin, which turns a minutes-scale peptide into a week-scale one. This is one of the few secretagogues with published human dose-ranging data measuring sustained IGF-1 elevation.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- GHRH analogue with albumin-binding drug affinity complex
- Reported half-life
- Approximately 6–8 days
- Routes used in the literature
- Subcutaneous and intravenous in the published trials
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Repeated-administration human arms
- Reported quantity
- 60 µg/kg
- Frequency
- Weekly or twice weekly
- Study duration
- Up to 49 days in the published study
Sustained rather than pulsatile GH elevation is the defining, and most criticised, feature.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
CJC-1295 with DAC · 2 mg Vial
CJC-1295 DAC is dosed at 2 mg weekly via subcutaneous injection in educational protocols. A 2 mg vial reconstituted with bacteriostatic water yields about 2.0 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 1.0 mL bacteriostatic water → 2.0 mg/mL (2,000 mcg/mL) concentration.
- Typical weekly dose
- 2,000 mcg (2 mg) once weekly — the full vial per injection.
- Easy measuring
- At 2.0 mg/mL, 1 unit = 0.01 mL = 20 mcg on a U-100 insulin syringe; full dose = 100 units (1.00 mL).
- Storage
- Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Standard Weekly Approach (1 mL = 2.0 mg/mL)
| Week | Weekly Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Mixed with 3 ml of bacteriostatic water
The same arithmetic for every vial size CJC-1295 with DAC is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
CJC-1295 with DAC · 3 ml bacteriostatic water
| Vial size | Concentration | Per 1 unit | 2 mg = |
|---|---|---|---|
| 2 mg | 0.67 mg/ml | 7 mcg | 300 units |
| 5 mg | 1.67 mg/ml | 17 mcg | 120 units |
Unit columns use the range reported for this compound (2 mg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 2 mg vial in 2 mL of bacteriostatic water gives 1 mg/mL, so 0.1 mL draws 100 µg.
Open the reconstitution calculatorHow to read these figures
- Continuous elevation departs from natural pulsatile GH physiology — a point raised repeatedly in the literature.
- The long half-life means any effect, wanted or unwanted, persists for days.
- Verify from the certificate whether a vial is the DAC or non-DAC molecule; labels are frequently ambiguous.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · J Clin Endocrinol Metab · 2006 · PMID 16352683
Healthy adults received single or multiple subcutaneous doses of CJC-1295 (30-60-100-200-260-320 µg/kg tested across dose-escalation groups; a 2 mg/subject dose given every 7 or 14 days for multiple-dose cohorts), producing sustained elevations in GH and IGF-1.
View the record - [2]Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A, et al. (GHRH knockout mouse study) · Am J Physiol Endocrinol Metab · 2006 · DOI 10.1152/ajpendo.00201.2006
GHRH knockout mice were given once-daily subcutaneous injections of CJC-1295 at specified microgram-per-gram doses over several weeks, restoring normal body growth.
View the record
Search the databases yourself
Read the CJC-1295 with DAC research briefOther growth hormone compounds
AOD-9604hGH fragment 176-191CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogueCJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blendGHRP-2Hexapeptide GH secretagogue
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.